EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Metformin and small for gestational age babies: findings of a randomised placebo-controlled clinical trial of metformin in gestational diabetes (EMERGE)

Fidelma Dunne, Christine Newman, Alberto Alvarez-Iglesias, Paula O'Shea, Declan Devane, Paddy Gillespie, Aoife Egan, Martin O'Donnell, Andrew Smyth

Diabetologia · 2024

DOI: 10.1007/s00125-024-06252-y ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetologia, 2024. Verfasst von Fidelma Dunne und 8 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Nursing and Health Sciences, University of Galway, Galway, Ireland. Fidelma.dunne@universityofgalway.ie. Hauptthemen laut MEDLINE: Metformin, Infant, Small for Gestational Age, Diabetes, Gestational, Hypoglycemic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Health Research Board Ireland, National University Ireland, Galway.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/hypothesis Gestational diabetes mellitus (GDM) is associated with adverse perinatal outcomes because of suboptimal glucose management and glucose control and excessive weight gain. Metformin can offset these factors but is associated with small for gestational age (SGA) infants. We sought to identify risk factors for SGA infants, including the effect of metformin exposure on SGA status.

Methods

In this prespecified secondary analysis of the EMERGE trial, which evaluated the effectiveness of metformin vs placebo in treating GDM and found reduced gestational weight gain and longer time to insulin initiation with metformin use, we included women with a live-born infant and known infant birthweight and gestational age at delivery. We compared the numbers of SGA infants in both groups and explored baseline predictive factors to help identify those at highest risk of delivering an SGA infant.

Results

Baseline maternal characteristics were similar between SGA and non-SGA pregnancies. On multivariable-adjusted regression, no baseline maternal variables were associated with SGA status. Mothers of SGA infants were more likely to develop pre-eclampsia or gestational hypertension (18.2% vs 2.0%, p =0.001; 22.7% vs 5.4%, p =0.005, respectively); after multivariable adjustment, pre-eclampsia was positively associated with SGA status). Among SGA pregnancies, important perinatal outcomes including preterm birth, Caesarean delivery and neonatal care unit admission did not differ between the metformin and placebo groups (20.0% vs 14.3%, p =1.00; 50.0% vs 28.6%, p =0.25; 13.3% vs 42.9%, p =0.27, respectively). Conclusions/interpretation Pre-eclampsia was strongly associated with SGA infants. Metformin-exposed SGA infants did not display a more severe SGA phenotype than infants treated with placebo.

Trial registration

Clinical Trials.gov NCT02980276; EudraCT number: 2016-001644-19 Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminInfant, Small for Gestational AgeDiabetes, GestationalHypoglycemic AgentsHumansFemalePregnancyInfant, NewbornAdultBirth WeightGestational AgePregnancy OutcomeRisk FactorsGestational Weight Gain

Stichwörter der Autor:innen

Gestational diabetesMetforminSmall for gestational age

Substanzen

MetforminHypoglycemic Agents

Autor:innen und Institutionen

  • College of Medicine, Nursing and Health Sciences, University of Galway, Galway, Ireland. Fidelma.dunne@universityofgalway.ie.
  • HRB Clinical Research Facility Galway, University of Galway, Galway, Ireland. Fidelma.dunne@universityofgalway.ie.
  • Galway University Hospital, Newcastle Road, Galway, Ireland. Fidelma.dunne@universityofgalway.ie.
  • College of Medicine, Nursing and Health Sciences, University of Galway, Galway, Ireland.
  • HRB Clinical Research Facility Galway, University of Galway, Galway, Ireland.
  • Galway University Hospital, Newcastle Road, Galway, Ireland.

Förderung

  • NIDDK NIH HHS
  • Health Research Board Ireland
  • National University Ireland, Galway

Zitieren

APA

Dunne, F., Newman, C., Alvarez-Iglesias, A., O'Shea, P., Devane, D., Gillespie, P., Egan, A., O'Donnell, M., & Smyth, A. (2024). Metformin and small for gestational age babies: findings of a randomised placebo-controlled clinical trial of metformin in gestational diabetes (EMERGE). Diabetologia. https://doi.org/10.1007/s00125-024-06252-y

Vancouver

Dunne F, Newman C, Alvarez-Iglesias A, O'Shea P, Devane D, Gillespie P, et al. Metformin and small for gestational age babies: findings of a randomised placebo-controlled clinical trial of metformin in gestational diabetes (EMERGE). Diabetologia. 2024. doi:10.1007/s00125-024-06252-y

BibTeX
@article{Dunne2024,
  author = {Dunne, Fidelma and Newman, Christine and Alvarez-Iglesias, Alberto and O'Shea, Paula and Devane, Declan and Gillespie, Paddy and Egan, Aoife and O'Donnell, Martin and Smyth, Andrew},
  title = {Metformin and small for gestational age babies: findings of a randomised placebo-controlled clinical trial of metformin in gestational diabetes (EMERGE)},
  journal = {Diabetologia},
  year = {2024},
  doi = {10.1007/s00125-024-06252-y}
}
Kostenlos starten →